Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEH4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,672
Award facts
- Contract value 100% obligated
- $22,671.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,671.84 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The delivery order, issued on January 28, 2026, with an ultimate completion date of February 19, 2026, carries no set-aside designation, reflecting DMS Pharmaceutical Group's competitive standing in unrestricted federal procurement. This award falls under the company's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, demonstrating substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses an extensive range of therapeutics including specialty pharmaceuticals, biologics, vaccines, and medical consumables, serving military healthcare facilities worldwide. The PPV-G GEN V master contract, valued at $499,999,999 with completion through December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to fulfill the diverse and specialized pharmaceutical requirements of the military medical system through firm fixed-price delivery orders.
Quick answers
Who was awarded contract SPE2DR26FMEH4?
SPE2DR26FMEH4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FMEH4 worth?
The government has obligated $22,672 on SPE2DR26FMEH4.
Is contract SPE2DR26FMEH4 an order under another contract?
Yes. SPE2DR26FMEH4 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEH4 competed?
The extent of competition for SPE2DR26FMEH4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award